Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum aggregate milestone payment for achievement of specified annual net sales

+ References

No definition available.

+ Details

Name:	vir_MaximumAggregateSalesMilestonePayment
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum Milestone Payment For Achievement Of Specified Development And Regulatory

+ References

No definition available.

+ Details

Name:	vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum Number Of Other Infectious Disease Targets Selected

+ References

No definition available.

+ Details

Name:	vir_MaximumNumberOfOtherInfectiousDiseaseTargetsSelected
Namespace Prefix:	vir_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty payment obligation expiration period after first commercial sales.

+ References

No definition available.

+ Details

Name:	vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=vir_FirstSiRNAProductHBVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Alnylam Pharmaceuticals, Inc. (Details) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
	Oct. 31, 2017 USD ($) diseaseTarget	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development		$ 80,040	$ 151,463		$ 324,245	$ 367,617
Alnylam Pharmaceuticals Inc \| Alnylam Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development				$ 30,000
Royalty payment obligation expiration period after first commercial sales (in years)	10 years
Alnylam Pharmaceuticals Inc \| First Si R N A Product H B V \| Alnylam Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum number of other infectious disease targets selected by VirBio \| diseaseTarget	4
Maximum milestone payment for achievement of specified development and regulatory milestones				$ 145,000
Maximum aggregate sales milestone payment	$ 250,000